Leslie Trigg Reports 904-Share Sell-to-Cover on Form 4 for OM
Rhea-AI Filing Summary
Insider Form 4 summary: Leslie Trigg, Chair and CEO of Outset Medical, sold 904 shares of common stock on 08/15/2025 at $12.88 per share to satisfy tax withholding related to the vesting of 1,769 restricted stock units granted on January 6, 2023 and January 12, 2024. The sale is described as a "sell to cover" to meet withholding obligations and not a discretionary trade. After the transaction, Trigg beneficially owns 122,328 shares directly and 42,250 indirectly (41,666 via the Trigg 2002 Rev Trust and 584 via the Trigg Family Trust).
Positive
- Transaction was a sell-to-cover strictly to satisfy tax withholding obligations, not a discretionary sale
- Clear post-transaction ownership disclosed: 122,328 shares direct and 41,666 and 584 shares held indirectly via two trusts
- Filing provides explanatory note linking the sale to vesting of 1,769 RSUs granted on January 6, 2023 and January 12, 2024
Negative
- None.
Insights
TL;DR: Routine sell-to-cover tax withholding by CEO; not indicative of discretionary liquidation and has limited market impact.
The Form 4 discloses a small disposition of 904 shares at $12.88 to satisfy tax withholding on 1,769 vested RSUs. For a company-level investor assessment, this is a routine administrative transaction associated with equity compensation. The filing lists substantial residual ownership by the reporting person, including 122,328 shares direct and 42,250 shares indirect, which suggests continued alignment with shareholders. No new options, derivative activity, or large unplanned disposals are reported, so the disclosure is neutral for valuation models.
TL;DR: Compliance-focused transaction; documentation notes it was executed to meet withholding obligations, aligning with standard governance practices.
The explanatory note clarifies the sale was to cover tax withholding on vested RSUs rather than an open-market decision to reduce exposure. The Form 4 properly reports the transaction date, price, and post-transaction beneficial ownership across direct and trust holdings. This transparency meets Section 16 disclosure requirements and signals routine equity compensation administration rather than governance concerns such as sudden insider departures or opportunistic selling.